HIV-infected pts failing immune recovery on virologically-suppressive HAART mantain a highlyactivated/differentiated peripheral CD4 pool. We hypothesized that Maraviroc, by specifically targeting terminally-differentiated CCR5+CD4, might preserve the naive/central memory CD4 pool in these pts.
Immunological Efficacy of Maraviroc (MVC) as intensification strategy in HIV-infected patients(PTS) failing CD4 recovery on virologically-suppressive HAART.
FRANCISCI, Daniela;
2011
Abstract
HIV-infected pts failing immune recovery on virologically-suppressive HAART mantain a highlyactivated/differentiated peripheral CD4 pool. We hypothesized that Maraviroc, by specifically targeting terminally-differentiated CCR5+CD4, might preserve the naive/central memory CD4 pool in these pts.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
